Transpara, the world’s leading breast AI software, surpasses 5 million mammograms and 1 million tomosynthesis studies analyzed to help radiologists read mammograms
NIJMEGEN, Netherlands, Nov. 21, 2023 /PRNewswire/ — ScreenPoint Medical, announced that its TransparaR Breast AI has surpassed 5 million mammograms, including more than 1 million tomosynthesis (3D) exams analyzed to help radiologists in reading mammography exams. Transpara provides radiologists with a “second pair” of eyes that helps detect cancers earlier and reduce recovery rates.
Used by hundreds of sites worldwide, Transpara has set the standard for Breast AI, providing support to all major mammography gantry manufacturers and integrating into the radiology readout workflow in both read-only and read-only environments. double. ScreenPoint will showcase its industry-leading Transpara results at the upcoming 109th Annual Meeting of the Radiological Society of North America (RSNA), November 26-30, 2023 (South Hall
The clinical and workflow benefits of Transpara in improving the mammography assessment process have been the subject of several major research studies published in top-tier peer-reviewed journals throughout the year, including a recent publication in Radiology (Lauritzen , et al) in August demonstrating that Transpara, combined with two other measures, provided a superior measure of short-term risk relative to many current models (i.e., Gail, TC8) (see accompanying figure).
“As the most widely used breast AI in clinical practice, with 5 million mammograms and 1 million tomosynthesis exams analyzed, we are very proud that study after study continues to demonstrate the value Transpara brings to breast healthcare providers and patients. Regardless of country, patient age, breast density or patient ethnicity, Transpara delivers consistent results. Our developing offerings will continue to expand the reach and impact of the Transpara Portfolio to help radiologists detect cancer sooner and safely reduce workload,” explained Mark Koeniguer, CEO of ScreenPoint Medical.
Transpara has FDA approval and European regulatory approval (CE mark) for use with 2D and 3D mammograms from multiple manufacturers. Used by hundreds of leading centers in more than 30 countries, Transpara is designed to work simultaneously with radiologists. Research shows that up to 45% of interval cancers can be detected earlier using Transpara, while helping to reduce workload and optimize workflow.
About ScreenPoint Medical
ScreenPoint Medical translates cutting-edge machine learning research into technology accessible to radiologists to improve screening workflow, decision confidence, and breast cancer risk assessment. Transpara is trusted by radiologists around the world because it has been developed by experts in machine learning and image analysis and updated with feedback from users of world-renowned breast imagers. View all evidence at: https://screenpoint-medical.com/published-evidence/peer-reviewed-publications
Photo – https://mma.prnewswire.com/media/2282337…Logo – https://mma.prnewswire.com/media/1582198…
View original content: https://www.prnewswire.com/news-releases/screenpoint-medical-alcanza-nuevos-hitos-301994817.html
